Correlation Between Microsoft and ArriVent BioPharma,
Can any of the company-specific risk be diversified away by investing in both Microsoft and ArriVent BioPharma, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Microsoft and ArriVent BioPharma, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Microsoft and ArriVent BioPharma, Common, you can compare the effects of market volatilities on Microsoft and ArriVent BioPharma, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Microsoft with a short position of ArriVent BioPharma,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Microsoft and ArriVent BioPharma,.
Diversification Opportunities for Microsoft and ArriVent BioPharma,
-0.22 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Microsoft and ArriVent is -0.22. Overlapping area represents the amount of risk that can be diversified away by holding Microsoft and ArriVent BioPharma, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ArriVent BioPharma, and Microsoft is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Microsoft are associated (or correlated) with ArriVent BioPharma,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ArriVent BioPharma, has no effect on the direction of Microsoft i.e., Microsoft and ArriVent BioPharma, go up and down completely randomly.
Pair Corralation between Microsoft and ArriVent BioPharma,
Given the investment horizon of 90 days Microsoft is expected to generate 0.4 times more return on investment than ArriVent BioPharma,. However, Microsoft is 2.51 times less risky than ArriVent BioPharma,. It trades about -0.04 of its potential returns per unit of risk. ArriVent BioPharma, Common is currently generating about -0.05 per unit of risk. If you would invest 43,109 in Microsoft on August 30, 2024 and sell it today you would lose (810.00) from holding Microsoft or give up 1.88% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Microsoft vs. ArriVent BioPharma, Common
Performance |
| Timeline |
| Microsoft |
| ArriVent BioPharma, |
Microsoft and ArriVent BioPharma, Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Microsoft and ArriVent BioPharma,
The main advantage of trading using opposite Microsoft and ArriVent BioPharma, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Microsoft position performs unexpectedly, ArriVent BioPharma, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma, will offset losses from the drop in ArriVent BioPharma,'s long position.| Microsoft vs. Palo Alto Networks | Microsoft vs. Uipath Inc | Microsoft vs. Block Inc | Microsoft vs. Adobe Systems Incorporated |
| ArriVent BioPharma, vs. Magnite | ArriVent BioPharma, vs. Sphere Entertainment Co | ArriVent BioPharma, vs. WiMi Hologram Cloud | ArriVent BioPharma, vs. Grupo Televisa SAB |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |